[en] The 16-kDa N-terminal fragment of human prolactin (16K hPRL) is a potent angiostatic factor that inhibits tumor growth in mouse models. Using microarray experiments, we have dissected how the endothelial-cell genome responds to 16K hPRL treatment. We found 216 genes that show regulation by 16K hPRL, of which a large proportion turned out to be associated with the process of immunity. 16K hPRL induces expression of various chemokines and endothelial adhesion molecules. These expressions, under the control of nuclear factor-kappaB, result in an enhanced leukocyte-endothelial cell interaction. Furthermore, analysis of B16-F10 tumor tissues reveals a higher expression of adhesion molecules (intercellular adhesion molecule 1, vascular cell adhesion molecule 1, or E-selectin) in endothelial cells and a significantly higher number of infiltrated leukocytes within the tumor treated with 16K hPRL compared with the untreated ones. In conclusion, this study describes a new antitumor mechanism of 16K hPRL. Because cellular immunity against tumor cells is a crucial step in therapy, the discovery that treatment with 16K hPRL overcomes tumor-induced anergy may become important for therapeutic perspectives.
Research Center/Unit :
Giga-Cancer - ULiège
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Tabruyn, Sébastien ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Sabatel, Céline ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Nguyen, Ngoc-Quynh-Nhu ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Verhaeghe
Castermans, Karolien ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Malvaux, Ludovic ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Griffioen, A. W.
Martial, Joseph ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Struman, Ingrid ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Language :
English
Title :
The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation
Publication date :
2007
Journal title :
Molecular Endocrinology
ISSN :
0888-8809
eISSN :
1944-9917
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
Carmeliet P 2005 Angiogenesis in life, disease and medicine. Nature 438:932-936
Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA 1999 Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 96:1246-1251
Nguyen NQ, Tabruyn SP, Lins L, Lion M, Cornet AM, Lair F, Rentier-Delrue F, Brasseur R, Martial JA, Struman I 2006 Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proc Natl Acad Sci USA 103:14319-14324
Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH 2003 Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 63:386-393
Pan H, Nguyen NQ, Yoshida H, Bentzien F, Shaw LC, Rentier-Delrue F, Martial JA, Weiner RI, Struman I, Grant MB 2004 Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci 45:2413-2419
Bentzien F, Struman I, Martini JF, Martial JA, Weiner RI 2001 Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res 61:7356-7362
Tabruyn SP, Griffioen AW 2007 Molecular pathways of angiogenesis inhibition. Biochem Biophys Res Commun 355:1-5
Clapp C, Weiner RI 1992 A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 130:1380-1386
Lee H, Struman I, Clapp C, Martial JA, Weiner RI 1998 Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology 139:3696-3703
Tabruyn SP, Nguyen NQ, Cornet AM, Martial JA, Struman I 2005 The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases. Mol Endocrinol 19:1932-1942
D'Angelo G, Martini JF, Iiri T, Fantl WJ, Martial JA, Weiner RI 1999 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol 13:692-704
Martini JF, Piot C, Humeau LM, Struman I, Martial JA, Weiner RI 2000 The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol Endocrinol 14:1536-1549
Tabruyn SP, Sorlet CM, Rentier-Delrue F, Bours V, Weiner RI, Martial JA, Struman I 2003 The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-κB. Mol Endocrinol 17:1815-1823
Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, Kennedy BP, Wasserman WW 2005 oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res 33:3154-3164
Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM, Kieff E 2004 Role of NF-κB in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 78:4108-4119
Schindler U, Baichwal VR 1994 Three NF-κB binding sites in the human E-selectin gene required for maximal tumor necrosis factor α-induced expression. Mol Cell Biol 14:5820-5831
Charo IF, Ransohoff RM 2006 The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354:610-621
Steeber DA, Venturi GM, Tedder TF 2005 A new twist to the leukocyte adhesion cascade: intimate cooperation is key. Trends Immunol 26:9-12
Ulbrich H, Eriksson EE, Lindbom L 2003 Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 24:640-647
Dirkx AE, Oude Egbrink MG, Kuijpers MJ, van der Niet ST, Heijnen VV, Bouma-ter Steege JC, Wagstaff J, Griffioen AW 2003 Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 63:2322-2329
Griffioen AW, Damen CA, Blijham GH, Groenewegen G 1996 Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88:667-673
Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK 1996 During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 2:992-997
Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D 1999 Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13:1382-1397
Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE 2003 Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep 10:309-313
Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, Ohuchi A, Ohuchi K, Shiiba K, Kurokawa Y, Satomi S 2004 Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis. Br J Cancer 91:1711-1717
Pawelec G, Heinzel S, Kiessling R, Muller L, Ouyang Q, Zeuthen J 2000 Escape mechanisms in tumor immunity: a year 2000 update. Crit Rev Oncog 11:97-133
Kisseleva T, Song L, Vorontchikhina M, Feirt N, Kitajewski J, Schindler C 2006 NF-κB regulation of endothelial cell function during LPS-induced toxemia and cancer. J Clin Invest 116:2955-2963
Shono T, Ono M, Izumi H, Jimi SI, Matsushima K, Okamoto T, Kohno K, Kuwano M 1996 Involvement of the transcription factor NF-κB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 16:4231-4239
Baldwin AS 2001 Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 107:241-246
Olivier S, Close P, Castermans E, de Leval L, Tabruyn S, Chariot A, Malaise M, Merville MP, Bours V, Franchimont N 2006 Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-κB inhibition and gene expression signature. Mol Pharmacol 69:1615-1623
Gospodarowicz D, Massoglia S, Cheng J, Fujii DK 1986 Effect of fibroblast growth factor and lipoproteins on the proliferation of endothelial cells derived from bovine adrenal cortex, brain cortex, and corpus luteum capillaries. J Cell Physiol 127:121-136
Hellebrekers DM, Castermans K, Vire E, Dings RP, Hoebers NT, Mayo KH, Oude Egbrink MG, Molema G, Fuks F, van Engeland M, Griffioen AW 2006 Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 66:10770-10777
